SAN DIEGO, Oct. 13, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (“Apricus Bio” or the “Company”) (Nasdaq:APRI) (http://www.apricusbio.com) announced today the publication of an article in the peer-reviewed International Journal of Pharmaceutics, entitled, “Transdermal and Transbuccal Drug Delivery Systems: Enhancement Using Iontophoretic and Chemical Approaches,” which confirms the Company’s NexACT® technology (DDAIP.HCL) to be the most effective chemical enhancer among three used in a study for the transbuccal delivery of lidocaine HCL (“LHCL”), Nicotine hydrogen tartrate (“NHT”), as well as for the transdermal delivery of diltiazem HCl (“DHCI”).
